Another recent meta-analysis showed that pooled intention-to-treat analysis showed a reduced risk of stroke with SGLT2 inhibitors compared to DPP-4 inhibitors (hazard ratio HR, 0.89; 95% CI, 0.82–0.96; I2 = 25%; p = 0.25) and non-SGLT2 inhibitors (HR, 0.83; 95% CI, 0.77–0.91; I2 = 11%; p = 0.34). The gene discussed is SLC5A2; the disease is stroke disorder.